Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 80

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 80
---
 100.0 | %  |
| Change in fair value of derivative liabilities and earnout liabilities |     |                            |           - |   |     |                  |  2,900,000 |   |     |            |  (2,900,000 | ) |     |                   |  (100.0 | )% |
| Stock-based inducement expense                                         |     |                            |    (707,300 | ) |     |                  |          - |   |     |            |    (707,300 | ) |     |                   |  (100.0 | )% |
| Interest income (expense), net                                         |     |                            |      13,776 |   |     |                  |    (16,977 | ) |     |            |      30,753 |   |     |                   |   181.1 | %  |
| Total other income (expense), net                                      |     |                            |    (693,524 | ) |     |                  |  2,699,583 |   |     |            |  (3,393,107 | ) |     |                   |  (125.7 | )% |
| Net loss                                                               |     |                            |  (5,417,315 | ) |     |                  | (2,448,654 | ) |     |            |  (2,968,661 | ) |     |                   |   121.2 | %  |
| Deemed dividend on Series A, Series B and C Preferred Stock            |     |                            | (24,700,374 | ) |     |                  |          - |   |     |            | (24,700,374 | ) |     |                   |   100.0 | %  |
| Net loss attributable to common stockholders                           |     | $                          | (30,117,689 | ) |     | $                | (2,448,654 | ) |     | $          | (27,669,035 | ) |     |                   | 1,130.0 | %  |

Research and Development Expenses

Research and development expenses were $2,754,000 for the three months
ended June 30, 2025 as compared to $2,714,000 for the three months ended June 30, 2024, reflecting an increase of $40,000. The increase
was primarily attributable to an increase in clinical expenses of approximately $1